Main menu

Recent Pfizer Press Releases

4/28/15 7:00am EDT
PFIZER REPORTS FIRST-QUARTER 2015 RESULTS

Pfizer Inc. (NYSE:PFE) reported financial results for first-quarter 2015. The company manages its commercial operations through two distinct businesses: an Innovative Products business and an Established Products business.

more...
4/23/15 2:07pm EDT
Pfizer Hosts Annual Meeting Of Shareholders

Declares 28-Cent Second-Quarter 2015 Dividend

The board of directors of Pfizer Inc. today declared a 28-cent second-quarter 2015 dividend on the company’s common stock, payable June 2, 2015, to shareholders of record at the close of business on May 8, 2015. The second-quarter 2015 cash dividend will be the 306th consecutive quarterly dividend paid by Pfizer.

more...
4/21/15 10:00am EDT
Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer

Pfizer Inc. announced today that XALKORI® (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC).

more...
4/21/15 8:00am EDT
Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Pfizer today announced that the Phase 3 study investigating the treatment of inotuzumab ozogamicin met its first primary endpoint of demonstrating a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL) compared to that achieved with standard of care chemotherapy.

more...
4/20/15 8:00am EDT
Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

  • First of several registration trials expected to start in 2015 for the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer
  • Initiation and first patient treated in Phase III clinical study recruiting across approximately 290 sites in more than 30 countries
  • The primary endpoint of the study is overall survival (OS) in patients with programmed death-ligand 1 positive (PD-L1+) stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-containing doublet therapy

 

Merck KGaA, Darmstadt, Germany, and Pfizer Inc, New York, US, today announced the initiation and first patient treated in the international Phase III study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab (MSB0010718C), compared with docetaxel, in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior pl

more...
4/16/15 2:26pm EDT
Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders

Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 23.

more...
4/15/15 8:00am EDT
4/9/15 8:00am EDT
Pfizer Launches First Annual PCSK9 Competitive Grants Program to Advance Cardiovascular Disease Research

Pfizer Inc. today announced the launch of a new competitive grants program the company is funding to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease.

more...
4/7/15 8:00am EDT
Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)

 

  • In the second and third quarters of 2015, Merck KGaA, Darmstadt, Germany, and Pfizer will begin co-promoting XALKORI in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom)
  • In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck KGaA, Darmstadt, Germany
  • Co-promotion of XALKORI allows the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer to establish a combined oncology sales organization in key markets for the program

 

Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US, today announced the finalization of the co-promotion agreemen

more...
4/6/15 1:00pm EDT
3/30/15 11:06am EDT
Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit

NEW YORK--Pfizer Inc. announced today that Charles Reay Mackay, Ph.D., will join the company as Chief Scientific Officer for Pfizer’s Inflammation and Immunology Research Unit.

more...
3/24/15 10:00am EDT
Pfizer Invites Public To View And Listen To Webcast Of April 28 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 28, 2015. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2015 Performance Report, to be issued that morning.

more...
3/23/15 8:00am EDT
Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement. This announcement follows a decision by the U.S.

more...
3/20/15 1:00pm EDT
Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials

Detailed Results from OPT Pivotal Studies Along with Integrated Analysis of Safety Data from Psoriasis Global Clinical Development Program Presented at 73rd American Academy of Dermatology (AAD) Annual Meeting

Pfizer Inc.

more...
3/18/15 5:04pm EDT
Results of Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine

Study Showed a Significant Reduction in Vaccine-Type Pneumococcal Community-Acquired Pneumonia in Older Adults Given Prevenar 13

Pfizer Inc.

more...
3/12/15 4:30pm EDT
Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia

Pfizer Inc. (NYSE:PFE) announced today top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica® (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia (FM). The primary endpoint of the study was not achieved as there was not a statistically significant difference between pregabalin and placebo in mean pain score.

more...
3/3/15 8:35am EST
Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

Label Also Updated to Include Data From the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Pfizer Inc.

more...
2/26/15 12:29pm EST
CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk

Pfizer Inc. (NYSE: PFE) announced today that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend serogroup B meningococcal vaccination to help protect individuals at increased risk. Specifically, the ACIP voted to recommend serogroup B meningococcal vaccination for persons aged 10 years and older at increased risk for meningococcal disease, including:

more...

Pages